Combating poor-quality anti-malarial medicines: A call to action

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Bassat, Quique ^a,b   Tanner, Marcel ^c,d   Guerin, Philippe J ^e,f   Stricker, Kirstin ^g   Hamed, Kamal ^g  

^a Manhiça Health Research Center   (Mozambique)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e WorldWide Antimalarial Resistance Network   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anti malarials; Counterfeit drugs; Falsified; Malaria; Quality control; Substandard

Indexed keywords

ANTIMALARIAL AGENT; COUNTERFEIT DRUG;

HUMAN; INTERNATIONAL COOPERATION; MALARIA; PRIVATE SECTOR; PUBLIC HEALTH; QUALITY CONTROL;

ANTIMALARIALS; COUNTERFEIT DRUGS; HUMANS; INTERNATIONAL COOPERATION; MALARIA; PRIVATE SECTOR; PUBLIC HEALTH; QUALITY CONTROL;

EID: 84971554603     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1357-8     Document Type: Review

References (77)

1. WHO. World malaria report. Geneva: World Health Organization; 2015.
2. WHO. World malaria report. Geneva: World Health Organization; 2014.
3. Nayyar GML, Attaran A, Clark JP, Culzoni MJ, Fernandez FM, Herrington FM. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg. 2015;92(Suppl 6):113-8.
4. Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013;3:e002923.
5. Newton PN, Green MD, Mildenhall DC, Plançon A, Nettey H, Nyadong L, et al. Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J. 2011;10:352.
6. WHO. Survey of the quality of selected antimalarial medicines circulating in six countries of Sub-Saharan Africa (WHO/EMP/QSM/2011.1). Geneva: World Health Organization; 2011. http://www.who.int/medicines/publications/WHO-QAMSA-report.pdf. Accessed 12 May 2016.
7. Institute of Medicine (IOM). Countering the problem of falsified and substandard drugs. Washington, DC: The National Academies Press; 2013.
8. Tabernero P, Fernández FM, Green M, Guerin PJ, Newton PN. Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database. Malar J. 2014;13:139.
9. Newton PN, Green MD, Fernández FM. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol Sci. 2010;31:99-101.
10. Mackey TK, Liang BA, York P, Kubic T. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. The global pandemic of falsified medicines: laboratory and field innovations policies and perspectives. Am J Trop Med Hyg. 2015;92(Suppl 6):59-67.
11. Renschler JP, Walters KM, Newton PN, Laxminarayan R. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg. 2015;92(Suppl 6):119-26.
12. Pisani E. Antimicrobial resistance: what does medicine quality have to do with it? Review on antimicrobial resistance. 2015. http://amr-review.org/sites/default/files/ElizabethPisaniMedicinesQualitypaper.pdf. Accessed 12 May 2016.
13. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176-87.
14. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.
15. Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in Southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12:488-96.
16. Newton PN, Schellenberg D, Ashley EA, Ravinetto R, Green MD, ter Kuile FO, et al. Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ. 2015;350:h605.
17. WHO. Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (Technical report series, no. 961). Geneva: World Health Organization; 2011.
18. Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, et al. How to achieve international action on falsified and substandard medicines. BMJ. 2012;345:e7381.
19. World Health Organization. Definitions of SSFFC products website. http://www.who.int/medicines/regulation/ssffc/definitions/en/. Accessed 12 May 2016.
20. WorldWide Antimalarial Resistance Network. Drug quality and the fight against infectious diseases. 2014. http://www.wwarn.org/sites/default/files/attachments/documents/WWARNAntimalarialQualityBrochure.pdf. Accessed 12 May 2016.
21. United States Pharmacopeia Drug Quality and Information Program. Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda: November 2009. Rockville: The United States Pharmacopeial Convention; 2010. http://www.usp.org/sites/default/files/usp-pdf/EN/PQM/QAMSAReport.pdf. Accessed 12 May 2016.
22. WorldWide Antimalaria Resistance Network. The WWARN antimalarial quality surveyor. http://www.wwarn.org/about-us/drug-quality/wwarn-antimalarial-quality-surveyor. Accessed 12 May 2016.
23. Kaur H, Allan EL, Mamadu I, Hall Z, Ibe O, El Sherbiny M, et al. Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria. PLoS One. 2015;10:e0125577.
24. ACT Consortium Drug Quality Project Team, The IMPACT2 Study Team. Quality of artemisinin-containing antimalarials in Tanzania's private sector - results from a nationally representative outlet survey. Am J Trop Med Hyg. 2015;92(Suppl 6):75-86.
25. Ravinetto R, Ngeleka Mutolo D, de Spiegeleere B, Marini R, Hasker E, Schiavetti B. The quality of paediatric medicines supplied by private wholesalers in Kinshasa, DRC. Trop Med Int Health. 2015;20(Suppl 1):1-147.
26. Yong YL, Plançon A, Lau YH, Hostetler DM, Fernández FM, Green MD, et al. Collaborative health and enforcement operations on the quality of antimalarials and antibiotics in southeast Asia. Am J Trop Med Hyg. 2015;92(Suppl 6):105-12.
27. El-Duah M, Ofori-Kwakye K. Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in Ghana. J Vector Borne Dis. 2012;49:131-9.
28. Osei-Safo D, Agbonon A, Konadu DY, Harrison JJ, Edoh M, Gordon A, Gbeassor M, et al. Evaluation of the quality of artemisinin-based antimalarial medicines distributed in Ghana and Togo. Malar Res Treat. 2014;2014:806416.
29. Ezenduka CC, Ogbonna BO, Ekwunife OI, Okonta MJ, Esimone CO. Drugs use pattern for uncomplicated malaria in medicine retail outlets in Enugu urban, southeast Nigeria: implications for malaria treatment policy. Malar J. 2014;13:243.
30. Yeung S, Lawford HL, Tabernero P, Nguon C, van Wyk A, Malik N, et al. Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia. Am J Trop Med Hyg. 2015;92(Suppl 6):39-50.
31. Tabernero P, Mayxay M, Culzoni MJ, Dwivedi P, Swamidoss I, Allan EL, et al. A repeat random survey of the prevalence of falsified and substandard antimalarials in the Lao PDR: a change for the better. Am J Trop Med Hyg. 2015;92(Suppl 6):95-104.
32. WHO. Briefing on malaria treatment guidelines and artemisinin monotherapies. Geneva: World Health Organization, 2006. http://www.who.int/malaria/publications/atoz/meeting-briefing19april/en/. Accessed 12 May 2016.
33. Newton PN, Tabernero P, Dwivedi P, Culzoni MJ, Monge ME, Swamidoss I. Falsified medicines in Africa: all talk, no action. Lancet Glob Health. 2014;2:e509-10.
34. WHO. Assessment of medicines regulatory systems in sub-Saharan African countries: an overview of findings from 26 assessment reports (WHO/EMP/QSM/2010.4). Geneva: World Health Organization; 2010. http://apps.who.int/medicinedocs/documents/s17577en/s17577en.pdf. Accessed 12 May 2016.
35. Attaran A. Stopping murder by medicine: introducing the model law on medicine crime. Am J Trop Med Hyg. 2015;92(Suppl 6):127-32.
36. World Health Organization Regional Committee for Africa. Strengthening the capacity for regulation of medical products in the African Region (AFR/RC63/7). 2013. http://apps.who.int/iris/bitstream/10665/94308/1/AFR-RC63-7.pdf. Accessed 12 May 2016.
37. World Health Organization. Falsified meningitis vaccines circulating in West Africa. UPDATE. 2015. http://www.who.int/medicines/publications/drugalerts/VF-MenomuneAlertENversion.pdf?ua=1. Accessed 12 May 2016.
38. Green MD, Hostetler DM, Nettey H, Swamidoss I, Ranieri N, Newton PN. Integration of novel low-cost colorimetric, laser photometric, and visual fluorescent techniques for rapid identification of falsified medicines in resource-poor areas: application to artemether-lumefantrine. Am J Trop Med Hyg. 2015;92(Suppl 6):8-16.
39. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One. 2014;9:e90601.
40. WorldWide Antimalarial Resistance Network. Medicine quality. http://www.wwarn.org/about-us/medicine-quality. Accessed 12 May 2016.
41. Caillet C, Sichanh C, Syhakhang L, Delpierre C, Manithip C, Mayxay M, et al. Population awareness of risks related to medicinal product use in Vientiane Capital, Lao PDR: a cross-sectional study for public health improvement in low and middle income countries. BMC Public Health. 2015;15:590.
42. WHO. Global technical strategy for malaria 2016-2030. Geneva: World Health Organization; 2015. http://www.who.int/malaria/publications/atoz/9789241564991/en/. Accessed 12 May 2016.
43. WHO. Recommendations on the content of a survey protocol for surveys of the quality of medicines. Geneva: World Health Organization. 2014. http://www.who.int/medicines/areas/quality-safety/quality-assurance/WHO-SamplingProcedures-GeneralDocument-QAS14-590-10062014.pdf. Accessed 12 May 2016.
44. World Health Organization. Guidelines on the conduct of surveys of the quality of medicines. 2015. http://www.who.int/medicines/areas/quality-safety/quality-assurance/Guidelines-on-medicines-quality-surveys-QAS15-630-30062015.pdf. Accessed 12 May 2016.
45. World Health Organization. Medicinal product alert. http://www.who.int/medicines/publications/drugalerts/en/. Accessed 12 May 2016.
46. Access to Medicine Foundation. The 2016 access to medicine index: methodology. 2015. http://www.accesstomedicineindex.org/sites/2015.atmindex.org/files/2015methodology-2016accesstomedicineindex-accesstomedicinefoundation.pdf. Accessed 12 May 2016.
47. Pharmaceutical Security institute. http://psi-inc.org/index.cfm. Accessed 12 May 2016.
48. de Veij M, Vandenabeele P, Hall KA, Fernandez FM, Green MD, White NJ, et al. Fast detection and identification of counterfeit antimalarial tablets by Raman spectroscopy. J Raman Spectrosc. 2007;38:181-7.
49. Ho NT, Desai D, Zaman MH. Rapid and specific drug quality testing assay for artemisinin and its derivatives using a luminescent reaction and novel microfluidic technology. Am J Trop Med Hyg. 2015;92(Suppl 6):24-30.
50. Ranieri N, Tabernero P, Green MD, Verbois L, Herrington J, Sampson E, et al. Evaluation of a new handheld instrument for the detection of counterfeit artesunate by visual fluorescence comparison. Am J Trop Med Hyg. 2014;91(5):920-4.
51. Food and Drug Administration. FDA facts: FDA's counterfeit detection device CD-3. 2013. http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM349286.pdf. Accessed 12 May 2016.
52. Weaver AA, Lieberman M. Paper test cards for presumptive testing of very low quality antimalarial medications. Am J Trop Med Hyg. 2015;92(Suppl 6):17-23.
53. CertiRx Corportation. http://www.certirx.com/. Accessed 12 May 2016.
54. Bate R, Hess K. Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments. Malar J. 2010;9:157.
55. World Health Organization. Prequalification programme. A United Nations programme managed by WHO. http://www.apps.who.int/prequal/. Accessed 12 May 2016.
56. t'Hoen EF, Hogerzeil HV, Quick JD, Sillo HB. A quiet revolution in global public health: the World Health Organization's Prequalification Of Medicines Programme. J Public Health Policy. 2014;35:137-61.
57. World Health Organization. Prequalification of medicines by WHO. 2013. http://www.who.int/mediacentre/factsheets/fs278/en/. Accessed 12 May 2016.
58. World Health Organization. WHO list of prequalified quality control laboratories (38th edition). 2016. http://apps.who.int/prequal/lists/PQ-QCLabsList.pdf. Accessed 12 May 2016.
59. WorldWide Antimalaria Resistance Network. External quality assurance. http://www.wwarn.org/tools-resources/external-quality-assurance. Accessed 12 May 2016.
60. Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, et al. Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malar J. 2010;9:375.
61. Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the WorldWide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother. 2014;58:3889-94.
62. ACT consortium. Our research themes. http://www.actconsortium.org/pages/research-themes.html. Accessed 12 May 2016.
63. Promoting the Quality of Medicines. Promoting the Quality of Medicines in Developing Countries (PQM). http://www.usp.org/global-health-programs/promoting-quality-medicines-pqmusaid. Accessed 12 May 2016.
64. US Pharmacopeial Convention. Glossary of PQM Activities. http://www.usp.org/global-health-programs/promoting-quality-medicines-pqmusaid/pqm-news-resource-center/glossary-pqm-activities. Accessed 12 May 2016.
65. Global Fund. Global fund quality assurance police for pharmaceutical products. 2010. http://www.theglobalfund.org/documents/psm/PSM-QAPharm-Policy-en/. Accessed 12 May 2016.
66. Global Fund. Guide to global fund policies on procurement and supply management of health products. 2012. http://www.theglobalfund.org/documents/psm/PSM-ProcurementSupplyManagement-Guidelines-en/. Accessed 12 May 2016.
67. Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa. Southern Med Review. 2012;5:31-7.
68. The African Medicines Regulatory Harmonisation Consortium. AMRH initiative. 2010. http://www.who.int/medicines/areas/quality-safety/regulation-legislation/PL2-3.pdf. Accessed 12 May 2016.
69. Institute of Medicine (IOM). International regulatory harmonization amid globalization of drug development: workshop summary. Washington, DC: The National Academies Press; 2013.
70. APEC Harmonization Center. Brochure. http://www.nifds.go.kr/apec/assets/front/imgs/download/AHC-Brochure.pdf. Accessed 12 May 2016.
71. African Medicines Registration Harmonisation Initiative. Status and future plans. 2009. http://apps.who.int/medicinedocs/documents/s20130en/s20130en.pdf. Accessed 12 May 2016.
72. Cinnamond M, Woods T. The Joint Interagency Task Force and the Global Steering Committee for the quality assurance of health products: two new proactive approaches promoting access to safe and effective medicines. Am J Trop Med Hyg. 2015;92(Suppl 6):133-6.
73. WHO. The protocol to eliminate illicit trade in tobacco products. WHO framework convention on tobacco control. Geneva: World Health Organization; 2013.
74. Attaran A. Model law on medicine crime - Draft V.2.0. http://www.ssrn.com/abstract=2530087. Accessed 12 May 2016.
75. United Nations general assembly, human rights council. Promotion and protection of all human rights, civil, political, economic, social and cultural rights, including the right to development. A/HRC/23/L.10/Rev.1. 2013. http://www.ap.ohchr.org/documents/dpage-e.aspx?si=A/HRC/23/L.10/rev.1. Accessed 12 May 2016.
76. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci. 2003;270:545-54.
77. Klein EY, Smith DL, Boni MF, Laxminarayan R. Clinically immune hosts as a refuge for drug-sensitive malaria parasites. Malar J. 2008;7:67.